Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8868010 | 0.80 | DGAT1 (0.33) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL29488702 | 0.80 | DGAT1 (0.33) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL11387554 | 0.80 | DGAT1 (0.33) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL7474314 | 0.77 | TSHR (0.42) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL1088727 | 0.77 | CA1 (0.35) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL17109641 | 0.77 | CA12 (0.36) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL30689516 | 0.77 | CA12 (0.36) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL10608008 | 0.77 | SLC7A5 (0.41) | DGAT1CA1CA2CA7CTSK | |
| SCHEMBL8843937 | 0.77 | CA1 (0.35) | DGAT1CA1CA2CA7CTSK | |
| SCHEMBL17240285 | 0.77 | SLC7A5 (0.41) | DGAT1CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724379-B2 | Therapeutic agents with improved fibrinogen binding | HAEMOSTATIX LIMITED (GB) | 2017-08-08 | — | — | US | disclosed |
| CN-104974001-A | Method for synthesizing beta-branched chain alpha-amino ester | CHINESE ACAD INST CHEMISTRY | 2015-10-14 | — | — | CN | disclosed |
| US-8153839-B2 | Method for synthesis of keto acids or amino acids by hydration of acetylene compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090216044-A1 | METHOD FOR SYNTHESIS OF KETO ACIDS OR AMINO ACIDS BY HYDRATION OF ACETYLENE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1932824-A1 | METHOD FOR SYNTHESIS OF KETO ACID OR AMINO ACID BY HYDRATION OF ACETHYLENE COMPOUND | Japan Science and Technology Agency (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216044-A1 | METHOD FOR SYNTHESIS OF KETO ACIDS OR AMINO ACIDS BY HYDRATION OF ACETYLENE COMPOUND | AADAT, BCAT2, BCAT1 | DGAT1 1744/4885CA1 4/4885CA2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.